Glen S. Frick, MD, PhD is an NIH Fellowship-Trained Pharmacologist and Board-Certified Pediatrician with over fifteen years of extensive Phase 1-4 clinical trial experience. Glen has held key roles within the pharmaceutical industry, including GlaxoSmithKline, Wyeth/Pfizer, Shire and Endo. He has conducted clinical and translational medicine studies in Neurodegeneration, Respiratory, Inflammation, Psychiatry, Pain and Dermatology. Glen completed an MD/PhD program at SUNY-Downstate Medical Center obtaining his PhD in Developmental Neural & Behavioral Science. He served as Global Development Team Leader for the Vyvanse ADHD franchise during his five years at Shire and most recently comes from Endo where he was VP of Clinical Development overseeing all clinical development programs for Belbuca, Opana and Xiaflex.